JPWO2019236625A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019236625A5 JPWO2019236625A5 JP2020567510A JP2020567510A JPWO2019236625A5 JP WO2019236625 A5 JPWO2019236625 A5 JP WO2019236625A5 JP 2020567510 A JP2020567510 A JP 2020567510A JP 2020567510 A JP2020567510 A JP 2020567510A JP WO2019236625 A5 JPWO2019236625 A5 JP WO2019236625A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- independently selected
- membered
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 15
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 11
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 10
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 230000008733 trauma Effects 0.000 claims 4
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims 2
- 208000034693 Laceration Diseases 0.000 claims 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 102100031562 Excitatory amino acid transporter 2 Human genes 0.000 claims 1
- 208000035874 Excoriation Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000003698 Heroin Dependence Diseases 0.000 claims 1
- 101000866287 Homo sapiens Excitatory amino acid transporter 2 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 206010065604 Suicidal behaviour Diseases 0.000 claims 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 238000005299 abrasion Methods 0.000 claims 1
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims 1
- -1 aminosulfonylamino Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000003492 excitotoxic effect Effects 0.000 claims 1
- 231100000063 excitotoxicity Toxicity 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 208000029790 metamphetamine dependence Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024133796A JP7794910B2 (ja) | 2018-06-04 | 2024-08-09 | Ｅａａｔ２活性化因子およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680423P | 2018-06-04 | 2018-06-04 | |
| US201862680418P | 2018-06-04 | 2018-06-04 | |
| US62/680,423 | 2018-06-04 | ||
| US62/680,418 | 2018-06-04 | ||
| PCT/US2019/035452 WO2019236625A1 (en) | 2018-06-04 | 2019-06-04 | Eaat2 activators and methods of using thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133796A Division JP7794910B2 (ja) | 2018-06-04 | 2024-08-09 | Ｅａａｔ２活性化因子およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527636A JP2021527636A (ja) | 2021-10-14 |
| JP2021527636A5 JP2021527636A5 (https=) | 2022-07-29 |
| JPWO2019236625A5 true JPWO2019236625A5 (https=) | 2022-07-29 |
Family
ID=68771005
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567510A Pending JP2021527636A (ja) | 2018-06-04 | 2019-06-04 | Ｅａａｔ２活性化因子およびその使用方法 |
| JP2024133796A Active JP7794910B2 (ja) | 2018-06-04 | 2024-08-09 | Ｅａａｔ２活性化因子およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024133796A Active JP7794910B2 (ja) | 2018-06-04 | 2024-08-09 | Ｅａａｔ２活性化因子およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11702403B2 (https=) |
| EP (2) | EP4685140A1 (https=) |
| JP (2) | JP2021527636A (https=) |
| CN (1) | CN112533601B (https=) |
| AU (1) | AU2019282231B2 (https=) |
| CA (1) | CA3102762A1 (https=) |
| ES (1) | ES3041367T3 (https=) |
| IL (1) | IL279199B1 (https=) |
| WO (1) | WO2019236625A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3877376T3 (da) | 2018-11-06 | 2023-10-02 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
| CA3118908A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| AU2019374812B2 (en) | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CN113939295B (zh) * | 2019-03-20 | 2025-05-16 | 金翅雀生物公司 | 哒嗪酮及其使用方法 |
| EP4149621B1 (en) * | 2020-05-13 | 2024-10-30 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260756A (en) * | 1979-11-15 | 1981-04-07 | American Cyanamid Company | 6- And 8-heteroaryl-1,2,4-triazolo[4,3-b]pyridazines |
| US4404203A (en) * | 1981-05-14 | 1983-09-13 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| US4397854A (en) * | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| AU691673B2 (en) * | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| CA2742411A1 (en) * | 2000-09-18 | 2002-03-21 | Eisai R&D Management Co., Ltd. | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations |
| AUPR606401A0 (en) * | 2001-07-02 | 2001-07-26 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| JP2003313169A (ja) * | 2002-04-19 | 2003-11-06 | Otsuka Chemical Holdings Co Ltd | ４，４−ジフルオロ−３−ブテニル化合物及び農園芸用殺虫・殺ダニ剤 |
| ES2232306B1 (es) * | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| JP4890439B2 (ja) * | 2005-03-07 | 2012-03-07 | 杏林製薬株式会社 | ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| AU2008219166B2 (en) * | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| US8426412B2 (en) | 2008-04-08 | 2013-04-23 | Dow Agrosciences, Llc. | 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and their use as fungicides |
| EP2196465A1 (en) * | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| US9447075B2 (en) * | 2011-08-02 | 2016-09-20 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as EAAT2 activators |
| CN103664895B (zh) * | 2012-08-28 | 2018-02-27 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及其用途 |
| AU2013365926B9 (en) * | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| EP2953944B1 (en) * | 2013-02-07 | 2017-04-26 | Merck Patent GmbH | Pyridazinone-amides derivatives |
| LT2953952T (lt) * | 2013-02-07 | 2017-08-25 | Merck Patent Gmbh | Makrocikliniai piridazinono dariniai |
| KR102420322B1 (ko) * | 2014-06-17 | 2022-07-13 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포이노시타이드 3-키나아제 억제제로서 인돌리진 유도체 |
| CN106467495A (zh) * | 2015-08-19 | 2017-03-01 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及用途 |
| WO2017123991A1 (en) | 2016-01-15 | 2017-07-20 | The Brigham And Women's Hospital, Inc. | Pyridazine derivatives as eaat2 activators |
| WO2018081378A1 (en) * | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
-
2019
- 2019-06-04 EP EP25194190.2A patent/EP4685140A1/en active Pending
- 2019-06-04 CN CN201980052147.6A patent/CN112533601B/zh active Active
- 2019-06-04 JP JP2020567510A patent/JP2021527636A/ja active Pending
- 2019-06-04 IL IL279199A patent/IL279199B1/en unknown
- 2019-06-04 EP EP19815032.8A patent/EP3801528B1/en active Active
- 2019-06-04 AU AU2019282231A patent/AU2019282231B2/en active Active
- 2019-06-04 US US16/972,311 patent/US11702403B2/en active Active
- 2019-06-04 WO PCT/US2019/035452 patent/WO2019236625A1/en not_active Ceased
- 2019-06-04 ES ES19815032T patent/ES3041367T3/es active Active
- 2019-06-04 CA CA3102762A patent/CA3102762A1/en active Pending
-
2022
- 2022-10-04 US US17/959,654 patent/US12286420B2/en active Active
-
2023
- 2023-07-18 US US18/354,330 patent/US20240208936A1/en active Pending
-
2024
- 2024-08-09 JP JP2024133796A patent/JP7794910B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527636A5 (https=) | ||
| JP2020517607A5 (https=) | ||
| JP2014500235A5 (https=) | ||
| RU2014113548A (ru) | Нейроактивные стероиды, композиции и их применения | |
| JP2003535094A5 (https=) | ||
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| JP2017511794A5 (https=) | ||
| JP2021105002A5 (https=) | ||
| ECSP066730A (es) | Compuestos y procedimientos para uso | |
| JP2010523651A5 (https=) | ||
| RU2012101947A (ru) | Способы лечения и профилактики усталости | |
| JPWO2019236625A5 (https=) | ||
| JP2011525185A5 (https=) | ||
| RU2013105444A (ru) | Конденсированные гетероциклические производные в качестве модуляторов s1p | |
| JP2015522551A5 (https=) | ||
| JP2012515152A5 (https=) | ||
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| RU2018140250A (ru) | Пролекарство производного аминокислоты | |
| RU2015148927A (ru) | Производные изохинолина, стимулирующие нейрогенез | |
| JP2009511525A5 (https=) | ||
| JP2014518552A5 (https=) | ||
| IL273922B2 (en) | D-amino acid oxidase inhibitors and therapeutic uses thereof | |
| RU2013147917A (ru) | Новые модуляторы кортикальной дофаминергической и опосредованной nmda-рецептором глутаматергической нейротрансмиссии | |
| HRP20110196T1 (hr) | 3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije | |
| JP2008536844A5 (https=) |